Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Xu, J.M.

Search results

  • RSS Feed
(1 - 9 of 9)
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Reichardt, P.; Joensuu, H.; Casali, P.G.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Demetri, G.D. 2014
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics
Article / Letter to editor
metadata only
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Reichardt, P.; Demetri, G.D.; Jeffers, M.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Casali, P.G. 2014
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Article / Letter to editor
metadata only
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Casali, P.G. 2013
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes
Article / Letter to editor
metadata only
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of outcomes based on pretreatment characteristics
Joensuu, H.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Demetri, G.D. 2013
Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of outcomes based on pretreatment characteristics
Article / Letter to editor
metadata only
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST
Demetri, G.D.; Jeffers, M.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; ... ; Casali, P.G. 2013
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GIST
Article / Letter to editor
metadata only
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; ... ; GRID Study Investigators 2013
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Article / Letter to editor
metadata only
RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL
Nishida, T.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; ... ; GRID Investigators 2012
RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL
Article / Letter to editor
metadata only
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; ... ; GRID Invest 2012
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Article / Letter to editor
metadata only
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Demetri, G.D.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; ... ; GRID Invest 2012
Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial
Article / Letter to editor
metadata only